Tatiana A. Mitina

Tatiana A. Mitina

Auto-generated profile, based on publicly available information

Tatiana A. Mitina

M.F. Vladimirskiy Moscow regional research clinical Institute

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2021 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
AKAlexander Kulagin
Alexander Kulagin
VPVadim V Ptushkin
Vadim V Ptushkin
ELElena A Lukina
Elena A Lukina
IDIgor L Davydkin
Igor L Davydkin
AKAlexander V Korobkin
Alexander V Korobkin
DKDmitry Kudlay
Dmitry Kudlay
Currently, eculizumab is the main effective treatment for paroxysmal nocturnal hemoglobinuria (PNH). The aim of this randomized multicenter noninferiority study was to evaluate the efficacy and safety of the Biosimilar (Elizaria) in comparison with the Originator (Soliris) in patients with PNH. Biosimilar and Originator were administered at a dose of 600 mg weekly for 4 weeks at the initial stage in naive patients, as well as for maintenance therapy at a dose of 900 mg every 2 weeks in all patients. The primary endpoint was a comparative assessment of hemolytic activity based on the area under the lactate dehydrogenase (LDH) concentration–time curve during the maintenance therapy. Thirty-two (32) patients were randomized for therapy with Biosimilar (n = 16) or Originator (n = 16). The mean values of LDH concentration–time curve were similar in both treatment groups without statistically significant differences (p > 0.05). Evaluation of secondary endpoints has shown no statistically significant differences between the groups. Safety values were comparable in both treatment groups. The data obtained confirm that the Biosimilar is not inferior to the Originator in terms of the main efficacy parameter, and is also comparable with it in terms of safety and additional efficacy parameters. Clinicaltrials.gov identifier: NCT04463056

1 July 2024 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
AMAnait Levonovna Melikyan
Anait Levonovna Melikyan
ISI. N. Subortseva
I. N. Subortseva
AKAlla Mikhailovna Kovrigina
Alla Mikhailovna Kovrigina
VSV. A. Shuvaev
V. A. Shuvaev
EME. V. Morozova
E. V. Morozova
EPE. N. Parovichnikova
E. N. Parovichnikova
The development of National clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms provides the knowledge basis for decision making in diagnosis, therapy, prevention, and rehabilitation in compliance with evidence-based medicine principles in order to ensure appropriate medical care in a particular clinical setting. The clinical guidelines underly the choice of optimal methods of diagnosis, therapy, prevention, and rehabilitation as part of a patient’s medical care, the development of criteria for the assessment of medical care quality, medical care standards, medical care procedures, setting standards on equipment and management of diagnostic and therapeutic procedures, and provision of continuous medical education and advanced training for healthcare professionals. In 2013, a working group was formed to develop and formulate clinical guidelines on the treatment of myeloproliferative neoplasms. These guidelines were first published in 2014, afterwards they were revised and republished. The dynamic development of current hematology presupposes constant updating of knowledge and implementation of new diagnosis and treatment methods in clinical practice. In this context, clinical guidelines present a dynamic document to be continuously amended, expanded, and updated in accordance with scientific findings and new requirements of specialists who are directly involved in treatment activities. The present edition is an upgraded version of clinical guidelines with updated information on classification, diagnosis, prognosis, current methods of therapy, and their efficacy and tolerability assessment. The guidelines are intended for oncologists, hematologists, healthcare executives, and medical students.

14 November 2020 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
AMA. I. Martynov
A. I. Martynov
ABA. P. Baida
A. P. Baida
VBV. E. Balan
V. E. Balan
IBI. I. Baranov
I. I. Baranov
AKAnastasia Kaburova
Anastasia Kaburova
Резолюция экспертного совета “Актуальные вопросы железодефицита в Российской Федерации”

2 September 2021 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
AMA. L. Melikyan
A. L. Melikyan
ISI. N. Subortseva
I. N. Subortseva
VSV. A. Shuvaev
V. A. Shuvaev
EME. V. Morozova
E. V. Morozova
KLK. A. Lukina
K. A. Lukina
VSV. G. Savchenko
V. G. Savchenko
Introduction. Recommendations cover the current state of diagnosis and treatment of mastocytosis.Aim — а consolidation of the Russian experts’ opinion on treatment for adult mastocytosis.Main findings. The recommendations have been developed taking into account foreign literature, national experience and world clinical evidence on therapy for systemic and cutaneous mastocytoses, mast cell leukaemia and other mastocytosis forms. The significance of bone marrow and peripheral blood molecular genetic testing for the presence of KITD816V gene variants is demonstrated. The treatment regimens described are based on midostaurin, imatinib, cladribine, hydroxycarbamide, interferon alfa and haematopoietic stem cell transplantation. Prognosis in different forms of mastocytosis is provided.

12 August 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VPVadim V. Ptushkin
Vadim V. Ptushkin
MKMichail A. Kunst
Michail A. Kunst
TMTatiana A. Mitina
Tatiana A. Mitina
TKTatiana S. Konstantinova
Tatiana S. Konstantinova
NRNatalia N. Rachkova
Natalia N. Rachkova
ШВШелехова Татьяна Владимировна
Шелехова Татьяна Владимировна
Aim. The primary objective of the interim analysis of the MULTISPECT study was to evaluate the short-term efficacy of the treatment and long-term outcomes in cohorts of primary and pretreated patients with multiple myeloma (MM) receiving treatment in actual clinical practice in various regions of the Russian Federation. Secondary objectives were a description of the main characteristics of patients; analysis of the most commonly used therapy regimens of the 1st and later lines and the sequence of their changes; evaluation of the response to therapy. Additional objectives included evaluation of the effect of the new COVID-19 coronavirus infection on the course of MM in patients. Materials and methods. The study is an observational retrospective-prospective multicenter cohort study. For its implementation, a structured database of patients with MM was used, provided by hematologists of the centers affiliated for the study. Results. The study included 1,294 patients (cohort 1 806, cohort 2 488). In both cohorts, patients aged 6069 years were in the majority. 3 lines of therapy (L1, L2, L3) were used for cohort 1; in cohort 2, the 4th line of therapy was also used in 2 patients. The therapy regimens were analyzed for 290 (22.41%) of all patients in the study. Responses to therapy were analyzed for 214 patients of cohort 1 and 109 patients of cohort 2. Autologous and allogeneic hematopoietic stem cell transplantations were carried out for a limited proportion of patients in both cohorts. At the end of the study and upon presentation of its results, the status of patients was the following: 96% of patients in cohort 1 and 89% in cohort 2 were alive. The therapy regimens in both cohorts were characterized by variability. The most commonly used regimens in each of the lines of therapy have been identified. The most used therapy regimen in patients with MM of both cohorts was the VCD-regime. Rd-regime in cohort 1 and RD-regime in cohort 2 were the second most frequent used regimens. In patients of both cohorts, the therapy regimens including Bortezomib were most often used. Conclusion. The variety of therapy regimens used to treat MM in actual clinical practice may be due to the factors of availability of new medicines and updated recommendations for the treatment of the disease. Further, in the context of this study, a more detailed analysis of the efficacy of certain therapy regimens in the 1st and later lines on progression free survival and overall survival of MM patients should be carried out.

8 December 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
SZS. G. Zakharov
S. G. Zakharov
TMT. A. Mitina
T. A. Mitina
AZA. V. Zakharova
A. V. Zakharova
RVR. V. Vardanyan
R. V. Vardanyan
EKE. V. Kataeva
E. V. Kataeva
ЮЧЮ. Б. Черных
Ю. Б. Черных
Glucocorticosteroids (GCS) are the first-line treatment for idiopathic thrombocytopenic purpura (ITP). Despite their high efficacy in patients with newly diagnosed ITP, an adequate level of platelets remains after GCS withdrawal in only less than 20 % of patients. Additionally, GCS use is associated with an increased risk of different adverse reactions, including serious and life-threatening ones. Thrombopoietin receptor agonists represent a relatively new class of drugs for treating ITP as a second-line therapy. This paper reviews the risks of GCS pharmacotherapy, as well as the evidence supporting the use of thrombopoietin receptor agonists as both first-line and second-line treatment for patients with ITP.